Literature DB >> 28481968

Concordance measure and discriminatory accuracy in transformation cure models.

Yilong Zhang1, Yongzhao Shao2.   

Abstract

Many populations of early-stage cancer patients have non-negligible latent cure fractions that can be modeled using transformation cure models. However, there is a lack of statistical metrics to evaluate prognostic utility of biomarkers in this context due to the challenges associated with unknown cure status and heavy censorship. In this article, we develop general concordance measures as evaluation metrics for the discriminatory accuracy of transformation cure models including the so-called promotion time cure models and mixture cure models. We introduce explicit formulas for the consistent estimates of the concordance measures, and show that their asymptotically normal distributions do not depend on the unknown censoring distribution. The estimates work for both parametric and semiparametric transformation models as well as transformation cure models. Numerical feasibility of the estimates and their robustness to the censoring distributions are illustrated via simulation studies and demonstrated using a melanoma data set.
© The Author 2017. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Concordance probability; Cure fraction; Mixture cure model; Predictive accuracy; Prognostics for censored survival; c-index

Mesh:

Year:  2018        PMID: 28481968      PMCID: PMC6075574          DOI: 10.1093/biostatistics/kxx016

Source DB:  PubMed          Journal:  Biostatistics        ISSN: 1465-4644            Impact factor:   5.899


  26 in total

1.  Estimation in a Cox proportional hazards cure model.

Authors:  J P Sy; J M Taylor
Journal:  Biometrics       Date:  2000-03       Impact factor: 2.571

2.  Interval mapping of quantitative trait loci for time-to-event data with the proportional hazards mixture cure model.

Authors:  Mengling Liu; Wenbin Lu; Yongzhao Shao
Journal:  Biometrics       Date:  2006-12       Impact factor: 2.571

3.  Assessing the fit of parametric cure models.

Authors:  E Paul Wileyto; Yimei Li; Jinbo Chen; Daniel F Heitjan
Journal:  Biostatistics       Date:  2012-11-28       Impact factor: 5.899

4.  Residual-based model diagnosis methods for mixture cure models.

Authors:  Yingwei Peng; Jeremy M G Taylor
Journal:  Biometrics       Date:  2016-09-06       Impact factor: 2.571

5.  Testing for improvement in prediction model performance.

Authors:  Margaret Sullivan Pepe; Kathleen F Kerr; Gary Longton; Zheyu Wang
Journal:  Stat Med       Date:  2013-01-07       Impact factor: 2.373

6.  Clinical trial designs for the early clinical development of therapeutic cancer vaccines.

Authors:  R M Simon; S M Steinberg; M Hamilton; A Hildesheim; S Khleif; L W Kwak; C L Mackall; J Schlom; S L Topalian; J A Berzofsky
Journal:  J Clin Oncol       Date:  2001-03-15       Impact factor: 44.544

7.  De Novo vs Nevus-Associated Melanomas: Differences in Associations With Prognostic Indicators and Survival.

Authors:  Rachel M Cymerman; Yongzhao Shao; Kun Wang; Yilong Zhang; Era C Murzaku; Lauren A Penn; Iman Osman; David Polsky
Journal:  J Natl Cancer Inst       Date:  2016-05-27       Impact factor: 13.506

8.  Sensitivity of plasma BRAFmutant and NRASmutant cell-free DNA assays to detect metastatic melanoma in patients with low RECIST scores and non-RECIST disease progression.

Authors:  Gregory A Chang; Jyothirmayee S Tadepalli; Yongzhao Shao; Yilong Zhang; Sarah Weiss; Eric Robinson; Cindy Spittle; Manohar Furtado; Dawne N Shelton; George Karlin-Neumann; Anna Pavlick; Iman Osman; David Polsky
Journal:  Mol Oncol       Date:  2015-09-25       Impact factor: 6.603

9.  Nivolumab plus ipilimumab in advanced melanoma.

Authors:  Jedd D Wolchok; Harriet Kluger; Margaret K Callahan; Michael A Postow; Naiyer A Rizvi; Alexander M Lesokhin; Neil H Segal; Charlotte E Ariyan; Ruth-Ann Gordon; Kathleen Reed; Matthew M Burke; Anne Caldwell; Stephanie A Kronenberg; Blessing U Agunwamba; Xiaoling Zhang; Israel Lowy; Hector David Inzunza; William Feely; Christine E Horak; Quan Hong; Alan J Korman; Jon M Wigginton; Ashok Gupta; Mario Sznol
Journal:  N Engl J Med       Date:  2013-06-02       Impact factor: 91.245

10.  One statistical test is sufficient for assessing new predictive markers.

Authors:  Andrew J Vickers; Angel M Cronin; Colin B Begg
Journal:  BMC Med Res Methodol       Date:  2011-01-28       Impact factor: 4.615

View more
  7 in total

1.  Application of Concordance Probability Estimate to Predict Conversion from Mild Cognitive Impairment to Alzheimer's Disease.

Authors:  Xiaoxia Han; Yilong Zhang; Yongzhao Shao
Journal:  Biostat Epidemiol       Date:  2017-07-31

2.  [Subgroup identification based on an accelerated failure time model combined with adaptive elastic net].

Authors:  Pei Kang; Jun Xu; Fuqiang Huang; Yingxin Liu; Shengli An
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2019-10-30

3.  Multicellular biomarkers of drug resistance as promising targets for glioma precision medicine and predictors of patient survival.

Authors:  Yuting Lu; Yongzhao Shao
Journal:  Cancer Drug Resist       Date:  2022-06-02

4.  Network-based survival analysis to discover target genes for developing cancer immunotherapies and predicting patient survival.

Authors:  Xinwei He; Xiaoqiang Sun; Yongzhao Shao
Journal:  J Appl Stat       Date:  2020-09-03       Impact factor: 1.416

5.  A numerical strategy to evaluate performance of predictive scores via a copula-based approach.

Authors:  Yilong Zhang; Yongzhao Shao
Journal:  Stat Med       Date:  2020-05-11       Impact factor: 2.373

6.  [Subgroup identification based on accelerated failure time model combined with adaptive elastic net].

Authors:  H Wei; P Kang; Y Liu; F Huang; Z Chen; S An
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2021-03-25

7.  Comparison of Long-term Survival Benefits in Trials of Immune Checkpoint Inhibitor vs Non-Immune Checkpoint Inhibitor Anticancer Agents Using ASCO Value Framework and ESMO Magnitude of Clinical Benefit Scale.

Authors:  Louis Everest; Monica Shah; Kelvin K W Chan
Journal:  JAMA Netw Open       Date:  2019-07-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.